Deferred Tax Assets, Valuation Allowance in USD of Coherus Oncology, Inc. from Q4 2013 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Coherus Oncology, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and change rate from Q4 2013 to Q4 2024.
  • Coherus Oncology, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $413M, a 2.49% decline year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Coherus Oncology, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed
Q4 2024 $413M -$10.6M -2.49% 31 Dec 2024 8-K 13 Nov 2025
Q4 2023 $423M +$85.6M +25.3% 31 Dec 2023 8-K 13 Nov 2025
Q4 2022 $338M +$64.4M +23.6% 31 Dec 2022 10-K 15 Mar 2024
Q4 2021 $273M +$72.4M +36% 31 Dec 2021 10-K 06 Mar 2023
Q4 2020 $201M -$22.7M -10.2% 31 Dec 2020 10-K 23 Feb 2022
Q4 2019 $224M -$13.4M -5.65% 31 Dec 2019 10-K 25 Feb 2021
Q4 2018 $237M +$54.6M +30% 31 Dec 2018 10-K 27 Feb 2020
Q4 2017 $182M +$4.61M +2.6% 31 Dec 2017 10-K 28 Feb 2019
Q4 2016 $178M +$43M +31.9% 31 Dec 2016 10-K 08 Mar 2018
Q4 2015 $135M +$79.2M +142% 31 Dec 2015 10-K 14 Mar 2017
Q4 2014 $55.6M +$22.1M +66% 31 Dec 2014 10-K 29 Feb 2016
Q4 2013 $33.5M 31 Dec 2013 10-K 23 Mar 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.